<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title42.html">
                                    Title 42
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/42CFR414.html">Part 414
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 414.906  Competitive acquisition program as the basis for payment.
                            </h3>
                            <p class="depth0"><em>(a)</em> Program payment. Beginning in 2006, as an alternative to payment  under Sec. 414.904, payment for a CAP drug may be made through the CAP  if the following occurs:</p><p class="depth0"><em>(1)</em> The CAP drug is supplied under the CAP by an approved CAP vendor  as specified in Sec. 414.908(b).</p><p class="depth0"><em>(2)</em> The claim for the prescribed drug is submitted by the approved  CAP vendor that supplied the drug, and payment is made only to that  vendor.</p><p class="depth0"><em>(3)</em> The approved CAP vendor collects applicable deductible and  coinsurance with respect to the drug furnished under the CAP only after  the drug is administered to the beneficiary.</p><p class="depth0"><em>(4)</em> The approved CAP vendor delivers CAP drugs directly to the  participating   CAP physician in unopened vials or other original containers as supplied  by the manufacturer or from a distributor that has acquired the products  directly from the manufacturer and includes language with the shipping  material stating that the drug was acquired in a manner consistent with  all statutory requirements. If the approved CAP vendor opts to split  shipments, the participating CAP physician must be notified in writing  which can be included with the initial shipment, and each incremental  shipment must arrive at least 2 business days before the anticipated  date of administration.</p><p class="depth0"><em>(5)</em> The approved CAP vendor bills Medicare only for the amount of  the drug administered to the patient, and the beneficiary's coinsurance  will be calculated from the quantity of drug that is administered.</p><p class="depth0"><em>(b)</em> Exceptions to competitive acquisition. Specific CAP drugs,  including a category of these drugs, may be excluded from the CAP if the  application of competitive bidding to these drugs--</p><p class="depth0"><em>(1)</em> Is not likely to result in significant savings; or</p><p class="depth0"><em>(2)</em> Is likely to have an adverse impact on access to those drugs.</p><p class="depth0"><em>(c)(2)</em> of this section, payment for CAP drugs is based on bids submitted  as a result of the bidding process as described in Sec. 414.910 of this  subpart.</p><p class="depth0"><em>(1)</em> Single payment amount. </p><p class="depth0"><em>(i)</em> A single payment amount for each CAP  drug in the competitive acquisition area is determined on the basis of  the bids submitted and accepted and updated from the bidding period to  the beginning of the payment year.</p><p class="depth0"><em>(ii)</em> The single payment amount is then updated quarterly based on  the approved CAP vendor's reasonable net acquisition costs for that  category as determined by CMS, and limited by the weighted payment  amount established under section 1847A of the Act across all drugs for  which a composite bid is required in the category.</p><p class="depth0"><em>(iii)</em> The payment amount for each other drug for which the approved  CAP vendor submits a bid in accordance with Sec. 414.910 of this subpart  and each other drug that is approved by CMS for the approved CAP vendor  to furnish under the CAP is also updated quarterly based on the approved  CAP vendor's reasonable net acquisition costs for each HCPCS code and  limited by the payment amount established under section 1847A of the  Act.</p><p class="depth0"><em>(2)</em> Updates to payment amount. </p><p class="depth0"><em>(i)</em> The first update is effective on  the first day of claims processing for the first quarter of an approved  CAP vendor's contract. The first quarterly contract update is based on  the reasonable net acquisition cost (RNAC) data reported to CMS or its  designee for any purchases of drug before the beginning of CAP claims  processing for the contract period and reported to CMS no later than 30  days before the beginning of CAP claims processing.</p><p class="depth0"><em>(ii)</em> For subsequent quarters, each approved CAP vendor must report  to CMS or its designee RNAC data for a quarter of CAP drug purchases  within 30 days of the close of that quarter.</p><p class="depth0"><em>(iii)</em> For all quarters, only RNAC data from approved CAP vendors  that are supplying CAP drugs under their CAP contract at the time  updates are being calculated must be used to calculate updated CAP  payment amounts.</p><p class="depth0"><em>(iv)</em> CMS excludes such RNAC data submitted by an approved CAP vendor  if, during the time calculations are being done, CMS knows that the  approved CAP vendor will not be under contract for the applicable  quarterly update.</p><p class="depth0"><em>(v)</em> The payment amount weights must be calculated based on the more  recent of the following:</p><p class="depth0"><em>(A)</em> Contract bidding weights.</p><p class="depth0"><em>(B)</em> CAP claims data.</p><p class="depth0"><em>(vi)</em> The payment limit must be determined using the most recent  payment limits available to CMS under section 1847A of the Act.</p><p class="depth0"><em>(vii)</em> The following payment amount update calculation must be  applied for the group of all drugs for which a composite bid is  required.</p><p class="depth0"><em>(A)</em> The most recent previous composite payment amount for the group  is updated by--</p><p class="depth0"><em>(1)</em> Calculating the percent change in reasonable net acquisition  costs for each approved CAP vendor;</p><p class="depth0"><em>(2)</em> Calculating the median of all participating approved CAP  vendors' adjusted CAP payment amounts; and</p><p class="depth0"><em>(3)</em> Limiting the payment as described in paragraph (c)(1) of this  section.</p><p class="depth0"><em>(B)</em> The median percent change, subject to the limit described in  paragraph (c)(1) of this section, must be the update percentage for that  quarter.</p><p class="depth0"><em>(C)</em> The single update percentage must be applied to the payment  amount for each drug in the group of drugs for which a composite bid is  required in the category.</p><p class="depth0"><em>(viii)</em> The following payment amount update calculation must be  applied for each of the following items: Each HCPCS code not included in  the composite bid list; Each HCPCS code added to the drug list during  the contract period; and each drug that has not yet been assigned a  HCPCS code, but for which a HCPCS code will be established.</p><p class="depth0"><em>(A)</em> The most recent previous payment amount for each drug must be  updated by calculating the percent change in reasonable net acquisition  costs for each approved CAP vendor, then calculating the median of all  participating approved CAP vendors' adjusted CAP payment amounts.</p><p class="depth0"><em>(B)</em> The median percent change calculated for each drug, subject to  the limit described in paragraph (c)(1) of this section, must be applied  to the payment amount for each drug.</p><p class="depth0"><em>(3)</em> Alternative payment amount. The alternative payment amount  established under section 1847A of the Act may be used to establish  payment for a CAP drug if--</p><p class="depth0"><em>(i)</em> The drug is properly assigned to a category established under  the CAP; and</p><p class="depth0"><em>(ii)</em> It is a drug for which a HCPCS code must be established.</p><p class="depth0"><em>(d)</em> Adjustments. There is an established process for adjustments to  payments to account for drugs that were billed, but which were not  administered.</p><p class="depth0"><em>(e)</em> Resupply of participating CAP physician drug inventory. A  participating CAP physician may acquire drugs under the CAP to resupply  his or her private inventory if all of the following requirements are  met:</p><p class="depth0"><em>(1)</em> The drugs were required immediately.</p><p class="depth0"><em>(2)</em> The participating CAP physician could not have anticipated the  need for the drugs.</p><p class="depth0"><em>(3)</em> The approved CAP vendor could not have delivered the drugs in a  timely manner. For purposes of this section, timely manner means  delivery within the emergency delivery timeframe, as defined in  Sec. 414.902.</p><p class="depth0"><em>(4)</em> The participating CAP physician administered the drugs in an  emergency situation, as defined in Sec. 414.902.</p><p class="depth0"><em>(f)</em> Substitution or addition of drugs on an approved CAP vendor's  CAP drug list--</p><p class="depth0"><em>(1)</em> Short-term substitution of a CAP drug. On an  occasional basis (for a period of time less than 2 weeks), an approved  CAP vendor may agree to furnish a substitute NDC within a HCPCS code on  the approved CAP vendor's CAP drug list if the approved CAP vendor--</p><p class="depth0"><em>(i)</em> Is willing to accept the payment amount that was established for  the HCPCS code under this section; and</p><p class="depth0"><em>(ii)</em> Obtains the participating CAP physician's prior approval.</p><p class="depth0"><em>(2)</em> Long-term substitution or addition of a CAP drug. An approved  CAP vendor may submit a request, as specified in paragraph (f)(3) of  this section, for approval to substitute an NDC supplied by the approved  CAP vendor for another NDC within the same HCPCS code or to add an NDC  to the approved CAP vendor's drug list, if at least one of the following  criteria is met:</p><p class="depth0"><em>(i)</em> Proposed substitution of an NDC for a period of 2 weeks or  longer.</p><p class="depth0"><em>(ii)</em> Proposed addition of one or more NDCs within a HCPCS code  included in the CAP drug category specified by CMS or on the approved  CAP vendor's approved CAP drug list.</p><p class="depth0"><em>(iii)</em> Proposed addition of--</p><p class="depth0"><em>(A)</em> One or more newly issued HCPCS codes; or</p><p class="depth0"><em>(B)</em> One of the following single indication orphan drug J codes or  their updates: J0205, J0256, J9300, J1785, J2355, J3240, J7513, J9010,  J9015, J9017, J9160, J9216.</p><p class="depth0"><em>(iv)</em> Beginning January 1, 2007, the proposed addition of a drug(s)  that has not yet been assigned a HCPCS code, but for which a HCPCS code  must be established.</p><p class="depth0"><em>(v)</em> On or after January 1, 2010, the proposed addition of drugs with  similar therapeutic uses to drugs already supplied under the CAP by the  approved CAP vendor(s).</p><p class="depth0"><em>(3)</em> Requesting the addition or substitution of CAP drug. An approved  CAP vendor that meets the one of the criteria specified in paragraph  (f)(2) must submit a written request to CMS or its designee. The request  must--</p><p class="depth0"><em>(i)</em> Specify the NDC(s) and the respective HCPCS code that is to be  added or substituted.</p><p class="depth0"><em>(ii)</em> Address the rationale for the substitution or addition of the  NDC(s) or the addition of the HCPCS code(s) as applicable; and</p><p class="depth0"><em>(iii)</em> Address the impact of the substitution of the NDC(s) or the  addition of the NDC(s) or HCPCS code(s), or both on--</p><p class="depth0"><em>(A)</em> Patient and drug safety;</p><p class="depth0"><em>(B)</em> Drug waste; and</p><p class="depth0"><em>(C)</em> The potential for cost savings.</p><p class="depth0"><em>(iv)</em> In the case of additions requested under paragraph (f)(2)(v) of  this section, address and document the need for such an expansion based  on demand for the product(s).</p><p class="depth0"><em>(4)</em> Approval of a request(s). CMS or its designee notifies the  approved CAP vendor of its decision.</p><p class="depth0"><em>(i)</em> Except as specified in paragraph (f)(4)(ii) of this section, an  approved request is effective at the beginning of the next calendar  quarter.</p><p class="depth0"><em>(ii)</em> Approved substitutions for request based on a drug shortage or  other exigent circumstance may become effective immediately provided  that--</p><p class="depth0"><em>(A)</em> CMS approves the immediate substitution; and</p><p class="depth0"><em>(B)</em> The approved CAP vendor's notifies its CAP participating  physicians of the substitution immediately following CMS approval.</p><p class="depth0"><em>(5)</em> Payment for an approved drug change(s). The payment for--</p><p class="depth0"><em>(i)</em> Substituted or added CAP drugs that are within a HCPCS code for  which payment is computed under paragraph (c)(1) of this section is the  single payment for that HCPCS code, as determined and updated in  accordance with paragraph (c)(1) of this section; or</p><p class="depth0"><em>(ii)</em> Added CAP drugs that are not within a HCPCS code for which  payment is computed under paragraph (c)(1) of this section is specified  under paragraph (c)(2) of this section.</p><p class="depth0"><em>(g)</em> Deletion of drugs on an approved CAP vendor's CAP drug list.  Deletion of drugs on an approved CAP vendor's CAP drug list due to  unavailability requires a written request and approval as described in  paragraphs (f)(3)(i) through (iii) and (f)(4) of this section.  [70 FR 39094, July 6, 2005, as amended at 70 FR 70333, Nov. 21, 2005; 71  FR 9460, Feb. 24, 2006; 74 FR 62012, Nov. 25, 2009]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
